Article
The RAD52 S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations.
Molecular oncology - 1 Jun 2020
Adamson Aaron W, Ding Yuan Chun, Mendez-Dorantes Carlos, Bailis Adam M, Stark Jeremy M, Neuhausen Susan L
Abstract excerpt
Women who carry pathogenic mutations in BRCA1 and BRCA2 have a lifetime risk of developing breast cancer of up to 80%. However, risk estimates vary in part due to genetic modifiers. We investigated the association of the RAD52 S346X variant as a modifier of the risk of developing breast and ovarian cancers in BRCA1 and BRCA2 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2. The RAD52...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.